TMO
Thermo Fisher Scientific
Is TMO Halal?
Life-science and laboratory tools are generally permissible, but current debt/assets fails the financial screens.
What You Should Know
Thermo Fisher's March 28, 2026 filing shows debt/assets of 38.10%, liquidity/assets of 2.87%, receivables plus cash/assets of 11.00% and disclosed interest income/revenue of 2.12%. Its life-science, diagnostics, clinical research, laboratory-products and biopharma-services businesses generally support research and health, while customer end uses and acquisition leverage require qualitative review.
⚠️ Concerns
- •Debt/assets is 38.10% and exceeds the examined FTSE, MSCI and Malaysia limits
- •Pharma services and clinical research require product, contract, patient-safety and research-ethics review
- •Government, defense-adjacent and dual-use customer exposure is not allocated
- •Disclosed interest income was 2.12% of quarterly revenue; acquisitions and supply-chain obligations require review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-28; calculated 2026-07-14.
43,161 / 113,281
3,256 / 113,281
12,458 / 113,281
233 / 11,005
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.10%, above the examined FTSE 33.333% limit; liquidity/assets is 2.87%, receivables plus cash/assets is 11.00% and interest income/revenue is 2.12%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.10%, above the examined MSCI 33.33% total-assets limit; the debt failure is independent of the incomplete activity classification.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 38.10%, above the examined Malaysia 33% limit; this is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the debt screen fails independently.
Business-activity disclosure
Thermo Fisher supplies life-science solutions, analytical instruments, specialty diagnostics, laboratory products, clinical research, pharmaceutical services and biopharma manufacturing. These activities generally support research and health, while product ingredients, clinical services, government work and downstream end uses require continuing qualitative review.
Limitation: The filing does not allocate revenue into a universal prohibited-activity numerator for biopharma services, clinical research, diagnostics, laboratory products, customer end uses or government-linked work.
Purification
Thermo Fisher discloses $233 million of interest income but does not prescribe a scholar-approved purification percentage; the disclosed ratio is evidence for the income screen, not a complete purification prescription.
Inputs, assumptions and primary sources
- Amounts are USD millions from Thermo Fisher's March 28, 2026 Form 10-Q and rounded to the nearest million.
- Debt includes $3,090 million of short-term obligations/current maturities and $40,071 million of long-term obligations; operating leases are excluded.
- Cash and cash equivalents are $3,254 million and short-term investments are $2 million.
- Accounts receivable, less allowances, are $9,204 million and first-quarter revenue is $11,005 million; disclosed interest income is $233 million.
- Thermo Fisher's fiscal quarter ended March 28, 2026 rather than calendar quarter-end.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →